These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date, and reported results 2004-000462-13 A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 300mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting... bad-data
Completed, but no date, and reported results 2004-000463-94 A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 600mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting... bad-data
Reported results 2004-000759-40 A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 15 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis. 2006-06-28 due-trials
Ongoing, reported early 2004-000762-13 A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 30 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis. not-yet-due
Listed as ongoing, but also has a completion date and reported results 2004-003943-28 A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the efficacy, tolerability and safety of two doses of laquinimod orally administered in re... 2006-06-28 bad-data
Listed as ongoing, but also has a completion date 2004-004612-23 A multi-center, randomized, double-blind, placebo-controlled, sequential cohort designed, escalating dose study to assess the tolerability, safety and maximal tolerated dose (MTD) of Ladostigil in pat... 2007-03-05 bad-data
Completed, but no date 2004-004901-12 Phase II randomized study of Combined Infusional Leucovorin Sodium and 5-FU Versus the Classical Sequential administration of Leucovorin Calcium followed by 5-FU both in combination with standard Iri... bad-data
Listed as ongoing, but also has a completion date and reported results 2005-001391-12 A Multi-National, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of Three Doses of Edratide TV-4710 f... 2007-02-28 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-001416-42 A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects 2008-11-27 bad-data
Listed as ongoing, but also has a completion date 2005-004334-41 An active extension of LAQ/5062 study. A multinational, multicenter, randomized, double-blind, parallel-group study, to evaluate the efficacy, tolerability and safety of two doses (0.3 mg and 0.6 mg) ... 2017-05-09 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-001688-49 A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of 40 mg Glatiramer Acetate for Injection in Subjects w... 2008-06-17 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-002037-20 A Multinational, Multicenter, Randomized, Parallel-Group, Double-Blind, Study, to Compare the Efficacy, Tolerability and Safety of Glatiramer Acetate Injection 40 mg/ml to that of Glatiramer Acetate I... 2008-12-02 bad-data
Ongoing, reported early 2006-005140-89 A PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJ... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2007-003226-19 A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in... 2010-11-08 bad-data
Reported results 2007-005450-23 A multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of laquinimod ov... 2011-06-29 due-trials
Not reported 2007-007455-14 A single-centre, open-label, randomised, 2-way cross-over study to determine the effects on the short-term lower leg growth rate between Qvar® 100 μg bd delivered via a metered dose inhaler (MDI) (TEV... 2008-12-18 due-trials
Reported results 2008-000709-12 Estudio prospectivo, abierto, aleatorizado del tratamiento de combinación de MYOCET® más ciclofosfamida y trastuzumab frente a doxorubicina libre más ciclofosfamida sola, seguidos cada uno de docetaxe... 2016-02-22 due-trials
Listed as ongoing, but also has a completion date 2008-002062-62 A Multinational, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of talampanel in Subjects with Amyotrophic Lateral Sc... 2010-07-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-004276-49 A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohorts, Dose Range Finding Study to Evaluate the Safety, Tolerability and Clinical Effect of Escalating Doses of Laq... 2011-11-24 bad-data
Reported results 2009-010562-31 Comparative bioavailability of Myfenax® (Teva) and CellCept® (Roche) in stable patients after renal transplantation 2010-10-18 due-trials
Completed, reported early 2009-011234-99 A Phase I, sequential group, randomized, double-blind, placebo-controlled study to assess the tolerability and safety of escalating doses of oral laquinimod administered 2013-05-23 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2009-011541-24 An open-label, multi-center, follow-up study designed to evaluate the long-term effects of rasagiline in Parkinson�s disease subjects who participated in the ADAGIO study 2013-02-28 bad-data
Listed as ongoing, but also has a completion date 2009-012989-30 A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-301 (ALLEGRO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laqui... 2017-05-09 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-014644-11 A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of t... 2011-10-19 bad-data
Not reported 2009-015815-42 A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-302 (BRAVO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquini... 2017-05-09 due-trials
Listed as ongoing, but also has a completion date 2009-018084-27 A multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer Ac... 2017-05-12 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-018329-20 A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Active Lupus Nephritis Patients, in Combination ... 2012-10-24 bad-data
Reported results 2010-019001-42 A Randomized, Double-Blind, Active Comparator, Non-Inferiority Study of Subcutaneously Administered Neugranin (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) or Pegfilgrastim i... 2012-02-23 due-trials
Completed, but no date 2010-019082-29 A double-blind, double-dummy, randomized, placebo- and active-controlled, three-way crossover study to evaluate the effect of Budesonide/Formoterol Spiromax® 80/4.5 mcg Inhalation Powder and Symbicort... bad-data
Listed as ongoing, but also has a completion date and reported results 2010-021011-16 A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination with Custirsen (OGX-011) in Men with Metastatic Castrate Resistant Prostate Cancer 2014-06-30 bad-data
Not reported 2010-023215-34 A Multinational, Multicenter, Randomized, Open-Label Study to Evaluate the Impact of a 91-day Extended Cycle Oral Contraceptive Regimen, Compared to two 28-day Standard Oral Contraceptive Regimens, ... 2011-12-02 due-trials
Reported results 2010-023342-67 A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) with E... 2013-09-12 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-023600-27 A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Twice Daily compared with Placebo in Adolescent and Adult Subje... 2013-07-10 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-023601-35 A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Orally Twice Daily compared with Placebo in Adolescent and Adul... 2013-10-10 bad-data
Reported results 2010-024006-35 A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations in Patients (12-75 ye... 2014-04-03 due-trials
Reported results 2010-024150-10 A-15 week, double-blind, randomized, active-controlled, multicenter study to evaluate the efficacy and safety of Alendronate plus Vitamin D3 in women with osteoporosis 2012-08-02 due-trials
Reported results 2010-024540-15 An Open-Label Extension Study to evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients with Eosinophilic Asthma who completed a prior Cephalon-sponsored Study ... 2015-01-16 due-trials
Reported results 2010-024614-66 A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations and Change in Lung Fu... 2014-03-04 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-002602-78 A Multinational, Multicenter, Randomized, Open-Label Study to Evaluate the Impact of DR-102 Compared to a 28-day Standard Oral Contraceptive Regimen, on Hemostatic Parameters in Healthy Women 2012-09-06 bad-data
Reported results 2011-004742-18 Multicenter, Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, Tolerability, and Immunogenicity of a Single, Subcutaneous Dose of 100μg/kg XM22 in 21 Children with E... 2015-04-21 due-trials
Listed as ongoing, but also has a completion date 2011-005021-48 A multicenter, double-blind, randomized, active controlled, parallel-group study to evaluate the efficacy, safety, tolerability and pharmacodynamic profiles of TL011 infusions compared with MabThera® ... 2012-08-01 bad-data
Reported results 2011-005550-57 A multinational, multicenter, randomized, parallel group, double blind, placebo controlled study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety... 2012-08-06 due-trials
Ongoing, reported early 2012-001107-20 A Phase 2a Randomised, Double-Blind, Placebo-Controlled Repeat Dose Trial of the Activity of MDT-637 in Healthy Subjects Challenged with RSV-A (Memphis 37b) not-yet-due
Ongoing 2012-001818-42 A Double-blind, Randomized, Sham–procedure–controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (rexlemestrocel-L) in Patients with Chronic Heart Failure Due ... not-yet-due
Reported results 2012-002447-14 A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic... 2016-11-17 due-trials
Reported results 2012-003413-33 A Randomized, Open-Label, Repeat Dosing (7 days), Four-Period Crossover Study to Compare the Pharmacokinetics, Efficacy and Safety of Tiotropium Bromide Delivered via Breath Actuated Inhaler (BAI), S... 2013-07-04 due-trials
Listed as ongoing, but also has a completion date 2012-003647-30 A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses ... 2017-05-09 bad-data
Reported results 2012-004975-37 A 64-Week (12-week core phase and 52-week safety extension), Phase II, Multicenter, Randomized, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults with Grow... 2015-06-22 due-trials
Not reported 2012-005432-28 An open label, randomized, active controlled, dose finding study to evaluate the pharmacodynamics, pharmacokinetics, efficacy and safety of balugrastim at doses of 300 μg/kg and 670 μg/kg in pediatric... 2014-11-13 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-000081-11 A 12-Week Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® 160/4.5 mcg Inhalation Powder Versus SYMBICORT® TURBOHALER® 200/6 mcg in Adult and Adolescent Patients with Persistent Asthm... 2014-03-20 bad-data
Completed, but no date, and reported results 2013-000208-41 A 12-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Once-Weekly Intra-Muscular Injections of TV-1380 (150 mg/week or 300 m... bad-data
Completed, report not yet due 2013-001284-23 A randomized, phase IIIB, open-label, two-arm, multicenter, comparatiVe study on efficacy and safety of lipegfilgrastim (Lonquex, TEVA) in comparison to pegfilgrastim (Neulasta®, Amgen) in elderly pat... 2018-04-24 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2013-001888-23 A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Pl... 2016-07-08 bad-data
Not reported 2013-002082-19 A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate the Efficacy, Safety and Tolerability of 2 Doses of Oral administration of L... 2014-02-19 due-trials
Reported results 2013-003397-27 A Randomized, Double Blind, Double Dummy, Placebo Controlled, Parallel Group, 12 Week Clinical Study to Assess the Efficacy and Safety Of 320 or 640 mcg/Day of Beclomethasone Dipropionate Delivered vi... 2014-11-12 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-004468-69 A Phase 2, Randomized, Open-Label, Safety and Dose-Finding Study Comparing 3 Different Doses of Weekly TV-1106 and Daily Recombinant Human Growth Hormone (Genotropin®) Therapy in Treatment-Naive, Pre-... 2016-04-29 bad-data
Reported results 2013-004630-14 A 12 Week, Randomized, Open-Label, Parallel Group Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) Spiromax(160/4.5 and 320/9 mcg) as Compared to SYMBICORT® TURBOHALER... 2015-03-13 due-trials
Reported results 2013-004632-30 A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 80 or 160 mcg/Day of Beclomethasone Dipropionate Delivered via... 2016-02-11 due-trials
Listed as ongoing, but also has a completion date 2014-000418-75 A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients wi... 2018-06-19 bad-data
Reported results 2014-000923-25 A 12-Week, Double-Blinded, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone/ Salmeterol Multidose Dry Powder Inhaler in A... 2015-09-26 due-trials
Reported results 2014-001149-25 A 12-Week, Double-Blinded, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone/ Salmeterol Multidose Dry Powder Inhaler in A... 2015-09-21 due-trials
Listed as ongoing, but also has a completion date and reported results 2014-001579-30 A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6... 2017-10-01 bad-data
Reported results 2014-001772-55 A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Efficacy, and Immunogenicity of Daily Subcutaneous Administration of 5 μg/kg tbo-filgrastim in... 2017-04-03 due-trials
Listed as ongoing, but also has a completion date and reported results 2014-002736-13 A phase 3, multicenter, randomized, open-label, comparator-controlled study to assess safety and tolerability of weekly TV-1106 compared to daily rhGH (Genotropin®) in adults with growth hormone-defic... 2015-12-18 bad-data
Listed as ongoing, but also has a completion date and reported results 2014-003796-32 A phase 3, multicenter, randomized, double-blind, placebo-controlled efficacy, safety and tolerability study of TV-1106 in growth hormone-deficient adults who are not current users of rhGH treatment 2015-12-28 bad-data
Listed as ongoing, but also has a completion date 2014-005096-85 Safety and Efficacy of LONQUEX® (Lipegfilgrastim) in Comparison to Pegfilgrastim (Neulasta®, Amgen Inc.) and Placebo in Patients with Non-Small-Cell Lung Cancer Receiving First-Line Chemotherapy 2018-02-09 bad-data
Ongoing 2015-000087-34 An Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Lipegfilgrastim 100 ?g/kg Body... not-yet-due
Completed, report not yet due 2015-000865-29 A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients with Uncontrolled Asthma and Elevated Blood Eosinophils 2018-01-31 not-yet-due
Completed, report not yet due 2015-000904-24 A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease 2017-10-27 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2015-000922-12 A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Treated with Subcutaneous In... 2017-06-02 bad-data
Completed, reported early 2015-001580-39 A Phase 3, 24-Week Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Reslizumab Subcutaneous Dosing (110 mg Every 4 weeks) in Patients with Oral Corticosteroid Dependent A... 2017-12-04 not-yet-due
Reported results 2015-004549-23 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for th... 2017-04-11 due-trials
Ongoing 2015-004550-18 A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV 48125 for the Preventive Treatment of Mi... not-yet-due
Reported results 2015-004598-34 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for th... 2017-04-11 due-trials
Ongoing 2016-000622-19 A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents not-yet-due
Other 2016-000630-22 An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (deutetrabenazine) for the Treatment of Tourette Syndrome in Children and ... not-yet-due
Listed as ongoing, but also has a completion date 2016-003171-21 A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-... 2018-06-15 bad-data
Ongoing 2016-003172-43 A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety and Efficacy of TEV-48125 for the Prevention of Cluster Headache not-yet-due
Ongoing 2016-003278-42 A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-... not-yet-due
Ongoing 2016-003835-39 A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone Propionate/Salmeterol Multidose Dry ... not-yet-due
Listed as ongoing, but also has a completion date 2016-004661-23 An Open-Label Extension Safety Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older with Severe Eosinophilic Asthma 2018-02-12 bad-data
No trial status on register 2017-002060-40 A Single-Dose, Open-Label, Parallel Group Study to Characterize the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of Reslizumab Following Subcutaneous Administration in ... bad-data
Ongoing 2017-002441-30 A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migrai... not-yet-due
Other 2017-002976-24 A Well-Controlled, Fixed-Dose Study of TEV 50717 (Deutetrabenazine) for the Treatment of Tics Associated with Tourette Syndrome not-yet-due